These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3089581)

  • 1. Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid.
    Nakanishi K; Zbar B; Borsos T; Glenn G
    Cancer Res; 1986 Aug; 46(8):3886-90. PubMed ID: 3089581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma therapy of primary rat mammary carcinoma: dependence of consumption of C3 during absorption of plasma with sepharose derivatives on the anticoagulant.
    Nakanishi K; Zbar B; Borsos T
    Cancer Res; 1985 Sep; 45(9):4122-7. PubMed ID: 3928150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma therapy of primary rat mammary carcinoma: antitumor activity of tumor-bearer plasma adsorbed against inactivated CNBr sepharose or protein A-sepharose.
    Sukumar S; Zbar B; Terata N; Langone JJ
    J Biol Response Mod; 1984; 3(3):303-15. PubMed ID: 6379113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotherapy of cancer: cellular changes in primary rat mammary carcinomas after infusion of syngeneic sera absorbed with protein A-Sepharose.
    Glenn GM; Szende B; Yano T; Zbar B; Borsos T
    Int J Cancer; 1988 Jul; 42(1):76-83. PubMed ID: 3292444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.
    Pinckard RN; Olson MS; Giclas PC; Terry R; Boyer JT; O'Rourke RA
    J Clin Invest; 1975 Sep; 56(3):740-50. PubMed ID: 808560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the alternate pathway in chelated serum.
    Forsgren A; Mclean RH; Michael AF; Quie PG
    J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracts of airborne grain dusts activate alternative and classical complement pathways.
    Olenchock SA; Mull JC; Major PC
    Ann Allergy; 1980 Jan; 44(1):23-8. PubMed ID: 6766283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
    Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
    J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of divalent-cation chelators and chloramphenicol on the spatial relationship of the nuclear envelope to chromatin in micronuclei of Chinese hamster cells.
    Chai LS; Weinfeld H; Sandberg AA
    J Supramol Struct; 1978; 9(4):459-71. PubMed ID: 108479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic effects of normal sera on lymphoid cells. II. Requirements for inhibition of nonspecific serum cytotoxicity by agarose.
    Budzko DB; Kierszenbaum F
    Transplantation; 1977 Apr; 23(4):337-42. PubMed ID: 405760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
    Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
    Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The septic burned patient: a model for studying the role of complement and immunoglobulins in opsonization of opportunist micro-organisms.
    Bjornson AB; Altemeier WA; Bjornson HS
    Ann Surg; 1979 Apr; 189(4):515-27. PubMed ID: 109057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the alternative pathway of complement by Acanthamoeba culbertsoni.
    Ferrante A; Rowan-Kelly B
    Clin Exp Immunol; 1983 Nov; 54(2):477-85. PubMed ID: 6418422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum.
    Hill AW; Shears AL; Hibbitt KG
    Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.
    Clas F; Loos M
    Immunology; 1980 Aug; 40(4):547-56. PubMed ID: 6776034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation by measles virus cytotoxic antibodies: alternative pathway C activation by hemagglutination-inhibition antibodies but classical activation by hemolysin antibodies.
    Ehrnst AC
    J Immunol; 1977 Feb; 118(2):533-9. PubMed ID: 402419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.